<p>Amneal Pharmaceuticals, Inc.（纳斯达克代码：AMRX - 获取免费报告）在覆盖该公司的五家研究公司中获得了 “适度买入” 的共识评级，Marketbeat.com 报道。一位研究分析师对该股票给予了持有建议，四位分析师则给予了买入建议。在过去一年中更新了对该股票覆盖的分析师中，平均 12 个月目标价为 13.50 美元。</p>
<p>获取 <strong>Amneal Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>3 个鲜为人知的医疗保健公司，未来潜力巨大</li>
</ul>
<p>AMRX 已成为多份研究报告的主题。Weiss Ratings 在 10 月 8 日的报告中重新发布了对 Amneal Pharmaceuticals 股票的 “持有（c）” 评级。巴克莱在 12 月 8 日的研究报告中开始覆盖 Amneal Pharmaceuticals。他们为该公司设定了 “增持” 评级和 15.00 美元的目标价。Piper Sandler 在 10 月 31 日的研究报告中重申了 “增持” 评级，并将 Amneal Pharmaceuticals 的目标价从 11.00 美元上调至 13.00 美元。最后，摩根大通在 9 月 16 日的报告中将 Amneal Pharmaceuticals 的目标价从 12.00 美元上调至 14.00 美元，并给予该公司 “增持” 评级。</p>
<p><strong>阅读我们关于 AMRX 的最新研究报告</strong></p>
<h2>Amneal Pharmaceuticals 的内部活动</h2>
<ul>
<li>6 个理由，为什么现在就该买入 Teva Pharmaceuticals 的股票</li>
</ul>
<p>在其他新闻中，董事 Ted C. Nark 于 11 月 17 日星期一出售了 50,000 股公司的股票，交易价格为每股 11.72 美元，总价值为 586,000.00 美元。交易完成后，该董事直接持有 291,029 股公司股票，价值为 3,410,859.88 美元。这笔交易代表了他们持股比例的 14.66% 的减少。该交易已在证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。此外，执行副总裁 Nikita Shah 于 11 月 12 日星期三出售了 131,856 股股票，交易价格为每股 11.92 美元，总交易额为 1,571,723.52 美元。交易完成后，该执行副总裁持有 146,403 股公司股票，价值为 1,745,123.76 美元。这代表了他们持股比例的 47.39% 的减少。该销售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士出售了 231,856 股公司股票，价值为 2,743,724 美元。26.56% 的股票由内部人士持有。</p>
<h2>机构投资者对 Amneal Pharmaceuticals 的看法</h2>
<p>几家对冲基金最近买入和卖出了该股票的股份。Mirabella Financial Services LLP 在第三季度购买了 Amneal Pharmaceuticals 的新股份，价值约为 147,000 美元。Tudor Investment Corp ET AL 在第三季度购买了 Amneal Pharmaceuticals 的新股份，价值约为 921,000 美元。CIBC Bancorp USA Inc. 在第三季度购买了 Amneal Pharmaceuticals 的新股份，价值约为 161,000 美元。Danske Bank A S 在第三季度购买了 Amneal Pharmaceuticals 的新股份，价值约为 1,092,000 美元。最后，Advisory Services Network LLC 在第三季度购买了 Amneal Pharmaceuticals 的新股份，价值约为 50,000 美元。目前，31.82% 的股票由机构投资者持有。</p>
<h2>Amneal Pharmaceuticals 股票表现</h2>
<p>纳斯达克：AMRX 的股票在周四开盘价为 12.96 美元。该公司的市值为 40.7 亿美元，市盈率为 648.07，贝塔值为 1.36。公司的 50 日移动平均线为 11.63 美元，200 日移动平均线为 9.88 美元。Amneal Pharmaceuticals 的 52 周低点为 6.68 美元，52 周高点为 12.98 美元。</p>
<p>Amneal Pharmaceuticals（纳斯达克：AMRX - 获取免费报告）最近在 10 月 30 日发布了季度财报。该公司报告每股收益（EPS）为 0.17 美元，超出分析师的共识预期 0.12 美元，超出幅度为 0.05 美元。该季度的营业收入为 7.8451 亿美元。Amneal Pharmaceuticals 的净利润率为 0.20%，股本回报率为负 185.60%。Amneal Pharmaceuticals 已设定 2025 财年的指导目标为 0.750-0.80 EPS。作为一个整体，研究分析师预测 Amneal Pharmaceuticals 本年度将发布 0.53 的每股收益。</p>
<h2>关于 Amneal Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Amneal Pharmaceuticals, Inc 是一家公开交易的综合医疗保健公司，专注于仿制药和特种药品的开发、生产和分销。该公司的产品组合包括口服固体剂型、注射剂、透皮剂和生物类似药，服务于心血管、神经科学、肿瘤学和女性健康等广泛的治疗领域。除了其仿制药产品外，Amneal 还通过战略收购和内部开发建立了品牌产品组合，使其在高销量仿制药和高价值特种治疗领域占据一席之地。</p>
<p>自 2002 年由兄弟 Chirag 和 Chintu Modgil 创立以来，Amneal 一直通过对研发的有机投资以及有针对性的并购追求增长。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Amneal Pharmaceuticals</li>
<li>请勿删除，立即阅读</li>
<li>投资者提醒：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉 AI，这将是下一个重大科技突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1SWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1SWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Amneal Pharmaceuticals 吗？</h2>
<p>在考虑 Amneal Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Amneal Pharmaceuticals 并不在名单上。</p>
<p>虽然 Amneal Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AMRX

<p>Amneal Pharmaceuticals（纳斯达克代码：AMRX）获得了五家研究公司的 “适度买入” 共识评级，12 个月的平均目标价为 13.50 美元。分析师的评级各不相同，有些分析师上调了他们的价格目标。内部交易活动包括公司高管的大量股票出售。机构投资者活跃，多个新投资组合被建立。该股票开盘价为 12.96 美元，市值为 40.7 亿美元。最近的财报超出预期，公司对 2025 财年的每股收益指导为 0.750-0.80 美元</p>

<p>Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has been given a consensus rating of &#34;Moderate Buy&#34; by the five research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $13.50.</p>
<div class="lb-trans"><p>Amneal Pharmaceuticals, Inc.（纳斯达克代码：AMRX - 获取免费报告）在覆盖该公司的五家研究公司中获得了 “适度买入” 的共识评级，Marketbeat.com 报道。一位研究分析师对该股票给予了持有建议，四位分析师则给予了买入建议。在过去一年中更新了对该股票覆盖的分析师中，平均 12 个月目标价为 13.50 美元。</p>
</div><p>Get <strong>Amneal Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Amneal Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>3 Lesser-Known Healthcare Names With Major Upside in Store</li>
</ul>
<div class="lb-trans"><ul>
<li>3 个鲜为人知的医疗保健公司，未来潜力巨大</li>
</ul>
</div><p>AMRX has been the subject of several research reports. Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Amneal Pharmaceuticals in a report on Wednesday, October 8th. Barclays started coverage on Amneal Pharmaceuticals in a research note on Monday, December 8th. They set an &#34;overweight&#34; rating and a $15.00 price target for the company. Piper Sandler restated an &#34;overweight&#34; rating and issued a $13.00 price objective (up from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Finally, JPMorgan Chase &amp; Co. upped their price objective on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an &#34;overweight&#34; rating in a report on Tuesday, September 16th.</p>
<div class="lb-trans"><p>AMRX 已成为多份研究报告的主题。Weiss Ratings 在 10 月 8 日的报告中重新发布了对 Amneal Pharmaceuticals 股票的 “持有（c）” 评级。巴克莱在 12 月 8 日的研究报告中开始覆盖 Amneal Pharmaceuticals。他们为该公司设定了 “增持” 评级和 15.00 美元的目标价。Piper Sandler 在 10 月 31 日的研究报告中重申了 “增持” 评级，并将 Amneal Pharmaceuticals 的目标价从 11.00 美元上调至 13.00 美元。最后，摩根大通在 9 月 16 日的报告中将 Amneal Pharmaceuticals 的目标价从 12.00 美元上调至 14.00 美元，并给予该公司 “增持” 评级。</p>
</div><p><strong>Read Our Latest Research Report on AMRX</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 AMRX 的最新研究报告</strong></p>
</div><h2>Insider Activity at Amneal Pharmaceuticals</h2>
<div class="lb-trans"><h2>Amneal Pharmaceuticals 的内部活动</h2>
</div><ul>
<li>6 reasons to buy Teva Pharmaceuticals stock sooner than later</li>
</ul>
<div class="lb-trans"><ul>
<li>6 个理由，为什么现在就该买入 Teva Pharmaceuticals 的股票</li>
</ul>
</div><p>In other news, Director Ted C. Nark sold 50,000 shares of the firm's stock in a transaction on Monday, November 17th. The stock was sold at an average price of $11.72, for a total value of $586,000.00. Following the completion of the transaction, the director directly owned 291,029 shares of the company's stock, valued at $3,410,859.88. This trade represents a 14.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, EVP Nikita Shah sold 131,856 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the completion of the sale, the executive vice president owned 146,403 shares in the company, valued at $1,745,123.76. This represents a 47.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 231,856 shares of company stock valued at $2,743,724. 26.56% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Ted C. Nark 于 11 月 17 日星期一出售了 50,000 股公司的股票，交易价格为每股 11.72 美元，总价值为 586,000.00 美元。交易完成后，该董事直接持有 291,029 股公司股票，价值为 3,410,859.88 美元。这笔交易代表了他们持股比例的 14.66% 的减少。该交易已在证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。此外，执行副总裁 Nikita Shah 于 11 月 12 日星期三出售了 131,856 股股票，交易价格为每股 11.92 美元，总交易额为 1,571,723.52 美元。交易完成后，该执行副总裁持有 146,403 股公司股票，价值为 1,745,123.76 美元。这代表了他们持股比例的 47.39% 的减少。该销售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士出售了 231,856 股公司股票，价值为 2,743,724 美元。26.56% 的股票由内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Amneal Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Amneal Pharmaceuticals 的看法</h2>
</div><p>Several hedge funds have recently bought and sold shares of the stock. Mirabella Financial Services LLP purchased a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter valued at about $147,000. Tudor Investment Corp ET AL purchased a new stake in Amneal Pharmaceuticals during the third quarter valued at approximately $921,000. CIBC Bancorp USA Inc. bought a new position in Amneal Pharmaceuticals in the third quarter worth approximately $161,000. Danske Bank A S bought a new position in Amneal Pharmaceuticals in the third quarter worth approximately $1,092,000. Finally, Advisory Services Network LLC bought a new stake in Amneal Pharmaceuticals during the third quarter valued at about $50,000. 31.82% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近买入和卖出了该股票的股份。Mirabella Financial Services LLP 在第三季度购买了 Amneal Pharmaceuticals 的新股份，价值约为 147,000 美元。Tudor Investment Corp ET AL 在第三季度购买了 Amneal Pharmaceuticals 的新股份，价值约为 921,000 美元。CIBC Bancorp USA Inc. 在第三季度购买了 Amneal Pharmaceuticals 的新股份，价值约为 161,000 美元。Danske Bank A S 在第三季度购买了 Amneal Pharmaceuticals 的新股份，价值约为 1,092,000 美元。最后，Advisory Services Network LLC 在第三季度购买了 Amneal Pharmaceuticals 的新股份，价值约为 50,000 美元。目前，31.82% 的股票由机构投资者持有。</p>
</div><h2>Amneal Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Amneal Pharmaceuticals 股票表现</h2>
</div><p>Shares of NASDAQ:AMRX opened at $12.96 on Thursday. The company has a market capitalization of $4.07 billion, a P/E ratio of 648.07 and a beta of 1.36. The company's 50-day moving average is $11.63 and its 200 day moving average is $9.88. Amneal Pharmaceuticals has a fifty-two week low of $6.68 and a fifty-two week high of $12.98.</p>
<div class="lb-trans"><p>纳斯达克：AMRX 的股票在周四开盘价为 12.96 美元。该公司的市值为 40.7 亿美元，市盈率为 648.07，贝塔值为 1.36。公司的 50 日移动平均线为 11.63 美元，200 日移动平均线为 9.88 美元。Amneal Pharmaceuticals 的 52 周低点为 6.68 美元，52 周高点为 12.98 美元。</p>
</div><p>Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.05. The business had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals had a net margin of 0.20% and a negative return on equity of 185.60%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. As a group, research analysts predict that Amneal Pharmaceuticals will post 0.53 earnings per share for the current year.</p>
<div class="lb-trans"><p>Amneal Pharmaceuticals（纳斯达克：AMRX - 获取免费报告）最近在 10 月 30 日发布了季度财报。该公司报告每股收益（EPS）为 0.17 美元，超出分析师的共识预期 0.12 美元，超出幅度为 0.05 美元。该季度的营业收入为 7.8451 亿美元。Amneal Pharmaceuticals 的净利润率为 0.20%，股本回报率为负 185.60%。Amneal Pharmaceuticals 已设定 2025 财年的指导目标为 0.750-0.80 EPS。作为一个整体，研究分析师预测 Amneal Pharmaceuticals 本年度将发布 0.53 的每股收益。</p>
</div><h2>About Amneal Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Amneal Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.</p>
<div class="lb-trans"><p>Amneal Pharmaceuticals, Inc 是一家公开交易的综合医疗保健公司，专注于仿制药和特种药品的开发、生产和分销。该公司的产品组合包括口服固体剂型、注射剂、透皮剂和生物类似药，服务于心血管、神经科学、肿瘤学和女性健康等广泛的治疗领域。除了其仿制药产品外，Amneal 还通过战略收购和内部开发建立了品牌产品组合，使其在高销量仿制药和高价值特种治疗领域占据一席之地。</p>
</div><p>Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&amp;A.</p>
<div class="lb-trans"><p>自 2002 年由兄弟 Chirag 和 Chintu Modgil 创立以来，Amneal 一直通过对研发的有机投资以及有针对性的并购追求增长。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Amneal Pharmaceuticals</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Amneal Pharmaceuticals</li>
<li>请勿删除，立即阅读</li>
<li>投资者提醒：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉 AI，这将是下一个重大科技突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1SWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=AMRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amneal Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Amneal Pharmaceuticals 吗？</h2>
</div><p>Before you consider Amneal Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Amneal Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amneal Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Amneal Pharmaceuticals 并不在名单上。</p>
</div><p>While Amneal Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Amneal Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) 获得分析师一致评级为 “适度买入”